#United States #Dallas #Cryoport Express #Cryogenic HV3 #Advanced Therapies

Cryoport's Revolutionary Shipping System for Biologics

Cryoport, Inc. has recently unveiled its innovative Cryogenic HV3 Shipping System at a prominent industry event in Dallas. This state-of-the-art solution is designed to enhance the transport of biologics and temperature-sensitive therapies, which are essential in life-saving medical treatments.

The newly developed Cryogenic HV3 is part of Cryoport's extensive portfolio of temperature-controlled shipping solutions. Unlike traditional shipping methods that often require palletization, the HV3 features a unique rectilinear design. This design not only eliminates the need for pallets but also facilitates the transport of critical materials via narrow-bodied aircraft, which is crucial for meeting regional carrier regulations. This advancement is expected to significantly reduce flight rejections and delays, thereby expanding the shipping lanes available for these essential therapies.

By ensuring enhanced protection and better accessibility for transporting biologics, the HV3 is poised to improve patient access to vital therapies in smaller cities and underserved areas. The advanced design also provides extra storage for non-temperature sensitive accessories and enhances operational efficiency by allowing shippers to be easily stacked and nested.

The Cryogenic HV3 goes beyond mere design improvements; it also incorporates full compliance with airline regulations and features an integrated condition and location monitoring system for complete Chain of Compliance. Operating at temperatures of -150°C or lower, it guarantees that payloads remain secure and stable throughout the transportation process. This is particularly important for advanced therapies that require stringent temperature control to maintain their integrity.

Furthermore, the HV3 has been engineered with mobility in mind, boasting robust wheels and an integrated front-facing handle, making it easier for clinicians and operators to manage it at point-of-care sites. Its scalability options also cater to higher density storage needs, efficiently integrating into various operational setups, from clinical sites to contract development and manufacturing organizations (CDMO's).

Cryoport remains committed to addressing the challenges faced in the life sciences supply chain by continuously innovating to meet the needs of its clients and the patients relying on these critical treatments. This dedication is reflected in their current offerings and future projects.

In a statement regarding the launch, CEO Jerrell Shelton emphasized their focus on patient access: "With the introduction of the Cryoport Express® Cryogenic HV3 Shipping System, we are improving patient access to vital cell therapies in smaller cities and remote areas, which will ultimately improve patient outcomes at large."

The HV3 Shipping System will be on display at Phacilitate's Advanced Therapies Week, where it will also be featured in a panel discussion on improving the supply chain in advanced therapies. According to Chief Product Development Officer Mike Dybicz, the HV3's innovative structure and enhanced features are expected to meet the growing demands of companies facing logistical challenges in transporting advanced therapies globally.

In summary, Cryoport's Cryogenic HV3 Shipping System represents a significant advancement in the transport of critical medical supplies, ensuring they reach patients who need them most. With its innovative design and focus on patient care, Cryoport continues to play a key role in enabling the future of medicine, affirming its position as a leader in supply chain solutions for the life sciences sector.